117 related articles for article (PubMed ID: 10194132)
1. Cytotoxic combination of loxoribine with fludarabine and mafosfamide on freshly isolated B-chronic lymphocytic leukemia cells.
Pellacani A; Tosi P; Zinzani PL; Ottaviani E; Albertini P; Magagnoli M; Tura S
Leuk Lymphoma; 1999 Mar; 33(1-2):147-53. PubMed ID: 10194132
[TBL] [Abstract][Full Text] [Related]
2. Loxoribine affects fludarabine activity on freshly isolated B-chronic lymphocytic leukemia cells.
Tosi P; Zinzani PL; Pellacani A; Ottaviani E; Magagnoli M; Tura S
Leuk Lymphoma; 1997 Jul; 26(3-4):343-8. PubMed ID: 9322897
[TBL] [Abstract][Full Text] [Related]
3. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia.
Bellosillo B; Villamor N; Colomer D; Pons G; Montserrat E; Gil J
Blood; 1999 Oct; 94(8):2836-43. PubMed ID: 10515887
[TBL] [Abstract][Full Text] [Related]
4. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.
Marotta G; Bigazzi C; Lenoci M; Tozzi M; Bocchia M; Lauria F
Haematologica; 2000 Dec; 85(12):1268-70. PubMed ID: 11114133
[TBL] [Abstract][Full Text] [Related]
5. Induction of "in vitro" apoptosis by fludarabine in freshly isolated B-chronic lymphocytic leukemia cells.
Zinzani PL; Buzzi M; Farabegoli P; Tosi P; Fortuna A; Visani G; Martinelli G; Zaccaria A; Tura S
Leuk Lymphoma; 1994 Mar; 13(1-2):95-7. PubMed ID: 8025527
[TBL] [Abstract][Full Text] [Related]
6. In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.
Kano Y; Akutsu M; Tsunoda S; Suzuki K; Ichikawa A; Furukawa Y; Bai L; Kon K
Leukemia; 2000 Mar; 14(3):379-88. PubMed ID: 10720130
[TBL] [Abstract][Full Text] [Related]
7. ZGDHu-1 and fludarabine have a synergistic effect on apoptosis of chronic lymphocytic leukemia cells.
Qiu L; Liu J; Wang Z; Hu W; Huang Q; Zhou Y
Oncol Rep; 2015 Sep; 34(3):1239-48. PubMed ID: 26165829
[TBL] [Abstract][Full Text] [Related]
8. Nitric oxide enhancement of fludarabine cytotoxicity for B-CLL lymphocytes.
Adams DJ; Levesque MC; Weinberg JB; Smith KL; Flowers JL; Moore J; Colvin OM; Silber R
Leukemia; 2001 Dec; 15(12):1852-9. PubMed ID: 11753605
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of action of the anti-VEGF monoclonal antibody bevacizumab on chronic lymphocytic leukemia cells.
Bogusz J; Majchrzak A; Mędra A; Cebula-Obrzut B; Robak T; Smolewski P
Postepy Hig Med Dosw (Online); 2013 Mar; 67():107-18. PubMed ID: 23475487
[TBL] [Abstract][Full Text] [Related]
10. Relationship between in vitro drug sensitivity and clinical response of patients to treatment in chronic lymphocytic leukemia.
Rogalińska M; Błoński JZ; Góralski P; Wawrzyniak E; Hartman M; Rogalska A; Robak P; Koceva-Chyła A; Piekarski H; Robak T; Kiliańska ZM
Int J Oncol; 2015 Mar; 46(3):1259-67. PubMed ID: 25572009
[TBL] [Abstract][Full Text] [Related]
11. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.
O'Brien SM; Kantarjian HM; Cortes J; Beran M; Koller CA; Giles FJ; Lerner S; Keating M
J Clin Oncol; 2001 Mar; 19(5):1414-20. PubMed ID: 11230486
[TBL] [Abstract][Full Text] [Related]
12. In vivo and ex vivo responses of CLL cells to purine analogs combined with alkylating agent.
Żołnierczyk JD; Borowiak A; Błoński JZ; Cebula-Obrzut B; Rogalińska M; Kotkowska A; Wawrzyniak E; Smolewski P; Robak T; Kiliańska ZM
Pharmacol Rep; 2013; 65(2):460-75. PubMed ID: 23744431
[TBL] [Abstract][Full Text] [Related]
13. New perspectives on the approach to chronic lymphocytic leukemia.
Goodman MG; Spinosa JC; Saven A; Piro LD; Wormsley S
Leuk Lymphoma; 1996 Jun; 22(1-2):1-10. PubMed ID: 8724523
[TBL] [Abstract][Full Text] [Related]
14. In vitro sensitivity of B-CLL cells to fludarabine and interferons.
Di Raimondo F; Palumbo GA; Romeo MA; Cacciola E; Milone G; Impera S; Giustolisi R; Cacciola E
Leuk Lymphoma; 1995 May; 17(5-6):449-53. PubMed ID: 7549836
[TBL] [Abstract][Full Text] [Related]
15. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
Robak T; Dmoszynska A; Solal-Céligny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Geisler CH; Montillo M; Zyuzgin I; Ganly PS; Dartigeas C; Rosta A; Maurer J; Mendila M; Saville MW; Valente N; Wenger MK; Moiseev SI
J Clin Oncol; 2010 Apr; 28(10):1756-65. PubMed ID: 20194844
[TBL] [Abstract][Full Text] [Related]
16. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
Flinn IW; Neuberg DS; Grever MR; Dewald GW; Bennett JM; Paietta EM; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS
J Clin Oncol; 2007 Mar; 25(7):793-8. PubMed ID: 17283364
[TBL] [Abstract][Full Text] [Related]
17. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
18. Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease.
Zecevic A; Sampath D; Ewald B; Chen R; Wierda W; Plunkett W
Clin Cancer Res; 2011 Jul; 17(14):4731-41. PubMed ID: 21632856
[TBL] [Abstract][Full Text] [Related]
19. In vitro chemosensitivity of chronic lymphocytic leukemia B-cells to multidrug regimen (CEOP) compounds using the MTT colorimetric assay.
Morabito F; Messina G; Oliva B; Ramirez F; Callea V; Brugiatelli M; Nobile F
Haematologica; 1993; 78(4):213-8. PubMed ID: 8294052
[TBL] [Abstract][Full Text] [Related]
20. Synergistic Activity of Deguelin and Fludarabine in Cells from Chronic Lymphocytic Leukemia Patients and in the New Zealand Black Murine Model.
Rebolleda N; Losada-Fernandez I; Perez-Chacon G; Castejon R; Rosado S; Morado M; Vallejo-Cremades MT; Martinez A; Vargas-Nuñez JA; Perez-Aciego P
PLoS One; 2016; 11(4):e0154159. PubMed ID: 27101369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
